39 enrolling by invitation. 39 Phase 2, 6 Phase 1, 6 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 39 | Enrolling by invitation 39 |
| Phase 1 | 6 | Enrolling by invitation 6 |
| Phase 3 | 6 | Enrolling by invitation 6 |
Follow Placebo: new trials by email Literature Review of Placebo trials Research Report on Placebo
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Efficacy of Intravenous Oxytocin to Speed Recovery After THA intravenous administration of oxytocin, Placebo - Total Hip Arthroplasty | Phase 2 | Enrolling by invitation | Wake Forest University Health Sciences | 80 | 2026-12-01 | 2026-10-23 |
| Herbal Supplement (Biocidin REMOVE) for Bacterial Overgrowth in Irritable Bowel Syndrome Biocidin REMOVE, Placebo - Irritable Bowel Syndrome (IBS), Small Intestinal Bacterial Overgrowth Syndrome (SIBO) | Phase 2 | Enrolling by invitation | Johns Hopkins University | 40 | 2026-10-26 | 2026-11-03 |
| The BANYAN Trial, an ALS MyMatch Trial Evaluating Safety, Biomarker Activity, and Microglial Activation of Nasal Foralumab Foralumab Nasal, Placebo - ALS (Amyotrophic Lateral Sclerosis), ALS - Amyotrophic Lateral Sclerosis | Phase 2 | Enrolling by invitation | Tiziana Life Sciences LTD | 44 | 2026-09-23 | 2026-10-28 |
| TLL-018 in Patients With Moderate to Severe Active Rheumatoid Arthritis With Inadequate Response or Intolerance to csDMARDs TLL-018, Placebo - Rheumatoid Arthritis (RA) | Phase 2 | Enrolling by invitation | Hangzhou Highlightll Pharmaceutical Co., Ltd | 90 | 2026-09-18 | 2026-09-28 |
| 9-cis Beta-Carotene-Rich Extract of Dunaliella Alga in Retinitis Pigmentosa Patients 9-cis beta-Carotene-rich extract of Dunaliella alga, Placebo Corn Oil - Retinitis Pigmentosa | Phase 1 / Phase 2 | Enrolling by invitation | Sheba Medical Center | 41 | 2026-07-26 | 2026-07-27 |
| TRACK-TBI Precision Medicine Part 3 - Option II Cyclosporine (CsA), Placebo - Traumatic Brain Injury | Phase 2 | Enrolling by invitation | University of California, San Francisco | 26 | 2026-07-02 | 2026-10-22 |
| Intravenous Iron to Improve Symptoms, Quality of Life and Exercise Capacity in HFpEF With Iron Deficiency Ferric Derisomaltose, Placebo - Heart Failure With Preserved Ejection Fraction (HFpEF | Phase 2 | Enrolling by invitation | Government of Jersey | 150 | 2026-06-19 | 2026-08-24 |
| This Study Aims to Determine Whether Lower Doses (4 µg) of Intrathecal Dexmedetomidine Can Provide Comparable Analgesic Benefits While Minimizing Adverse Hemodynamic Effects in Patients Encountered in Our Setup( Shifa International Hospital Islamabad). Intrathecal Dexmedetomidine, Placebo - Intrathecal Dexmedetomidine | Phase 1 / Phase 2 | Enrolling by invitation | Shifa International Hospital | 60 | 2026-05-04 | 2026-09-08 |
| QLS1410 in Participants With Uncontrolled Hypertension Dose 1 of QLS1410, Dose 2 of QLS1410, Dose 3 of QLS1410 - Hypertension (HTN) | Phase 2 | Enrolling by invitation | Qilu Pharmaceutical Co., Ltd. | 260 | 2026-04-01 | 2026-05-22 |
| Belumosudil for Abrogation of Interstitial Fibrosis and Tubular Atrophy Following Kidney Transplantation Belumosudil 200 mg QD, Placebo - Rejection Chronic Renal | Phase 2 | Enrolling by invitation | The Methodist Hospital Research Institute | 40 | 2025-09-11 | 2025-11-12 |
| Chronic Exogenous Ketosis in HFpEF Exogenous Ketone Drink, Placebo - Heart Failure With Preserved Ejection Fraction (HFPEF), Heart Failure With Normal Ejection Fraction | Phase 2 | Enrolling by invitation | Duke University | 20 | 2025-07-28 | 2026-10-14 |
| Efficacy Test of Curcuminoid Standardized Turmeric Capsules to Improving Inflammatory Biomarkers in Osteoarthritis Genu Curcuminoid Standardized Turmeric Capsules, Placebo - Osteoarthritis | Phase 2 / Phase 3 | Enrolling by invitation | Gadjah Mada University | 72 | 2025-06-01 | 2025-09-19 |
| Oral Ketorolac for IUD Pain Reduction Ketorolac, Placebo - IUD Insertion Pain | Phase 2 | Enrolling by invitation | University of North Carolina, Chapel Hill | 108 | 2025-05-23 | 2026-09-08 |
| Early Norepinephrine in Trauma Patients With Hemorrhagic Shock Norepinephrine, Placebo - Trauma, Multiple | Phase 1 / Phase 2 | Enrolling by invitation | Visarat Palitnonkiat | 40 | 2025-05-20 | 2025-05-18 |
| Neuroimaging of Escitalopram in Autism Spectrum Disorder Escitalopram 10mg, Placebo - Autism Spectrum Disorder | Phase 2 | Enrolling by invitation | Kathryn Unruh | 5 | 2025-04-28 | 2026-02-18 |
| Maternal Probiotic Intervention to Improve Gut Health - Trial II - Bangladesh VE818, Placebo, Oral Vancomycin - Environmental Enteric Dysfunction | Phase 2 | Enrolling by invitation | International Centre for Diarrhoeal Disease Research, Bangladesh | 144 | 2025-04-20 | 2025-12-10 |
| To Evaluate the Efficacy and Safety of TRD205 Tablets in the Treatment of Chronic Postoperative Neuralgia TRD205 tablets, Placebo - Chronic Postoperative Neuralgia | Phase 2 | Enrolling by invitation | Beijing Tide Pharmaceutical Co., Ltd | 184 | 2025-04-09 | 2025-08-17 |
| Mesenchymal Stem Cells Infusion in Patients With Autoimmune Diseases Mesenchymal Stem Cells, Placebo - Rheumatoid Arthritis, Systemic Lupus Erythematosus (SLE) | Phase 1 / Phase 2 | Enrolling by invitation | National Institute of Blood and Marrow Transplant (NIBMT), Pakistan | 200 | 2025-02-01 | 2025-03-21 |
| Effectiveness of Probiotics for the Prevention of Gastrointestinal Toxicity in Children With Leukemia Lactobacillus casei, Lactobacillus rhamnosus, Bifidobacterium bifidum - Probiotics, Gastrointestinal Diseases | Phase 2 | Enrolling by invitation | National Institute of Pediatrics, Mexico | 120 | 2025-02-01 | 2025-03-14 |
| Effect of Psiguavin for Obesity Treatment (PSIGUAVIN) Psiguavin, Placebo - Obesity, Overweight or Obesity | Phase 1 / Phase 2 | Enrolling by invitation | Universidad Católica San Antonio de Murcia | 100 | 2025-01-08 | 2024-07-22 |
Showing 20 of 39. Sign in to see all of them.
Arthritis, Rheumatoid (2) · Brain Injuries, Traumatic (2) · Heart Failure (2) · Osteoarthritis (2) · Pulmonary Fibrosis (2) · Accidental Injuries (1) · Amyotrophic Lateral Sclerosis (1) · Angina Pectoris (1) · Angina Pectoris, Variant (1) · Arthritis, Juvenile (1) · Asthma (1) · Autism Spectrum Disorder (1) · Autoimmune Diseases (1) · Bronchiectasis (1) · Bronchiolitis Obliterans Syndrome (1)
Duke University (2) · Haisco Pharmaceutical Group Co., Ltd. (2) · Mayo Clinic (2) · The Methodist Hospital Research Institute (2) · University of California, San Francisco (2) · Beijing Tide Pharmaceutical Co., Ltd (1) · Bryan Cotton (1) · Charles University, Czech Republic (1) · Gadjah Mada University (1) · Government of Jersey (1) · Guangzhou JOYO Pharma Co., Ltd (1) · Hangzhou Highlightll Pharmaceutical Co., Ltd (1) · Instituto Oncoclinicas (1) · International Centre for Diarrhoeal Disease Research, Bangladesh (1) · Johns Hopkins University (1)
United States (16) · China (7) · Netherlands (2) · Pakistan (2) · Spain (2) · Australia (1) · Bangladesh (1) · Brazil (1) · Canada (1) · Denmark (1) · Germany (1) · Hong Kong (1) · Indonesia (1) · Israel (1) · Italy (1)
Amy G Bryant, M.D. (1) · Andrew Mitchell (1) · Bryan A Cotton, MD (1) · Douglas Ririe, M.D. (1) · Geoffrey Manley, MD PhD (1) · Geoffrey Manley, MD, PhD (1) · Gerry Mullin, MD (1) · Jie Zhao, Dr (1) · John Aaron Henry (1) · Kathryn E Unruh, PhD (1) · Kvido Smitka, M.D., Ph.D. (1) · Memoona Haider, MBBS, FCPS (1) · Miriam Treggiari, MD (1) · Noreen Bukhari-Parlakturk, MD PhD (1)
PMID 11408503, PMID 11972517, PMID 14966830, PMID 15253677, PMID 17516870, PMID 17576459, PMID 19553647, PMID 21879172, PMID 23727426, PMID 23757085, PMID 24290319, PMID 24428625, PMID 24618152, PMID 24713845, PMID 24891990, PMID 25040088, PMID 25304690, PMID 25651996, PMID 26888258, PMID 28270698, PMID 28287336, PMID 28413626, PMID 28426102, PMID 28646338, PMID 29182564, PMID 29518185, PMID 30168576, PMID 31033786, PMID 31280227, PMID 31777071, PMID 31826366, PMID 40200322, PMID 40274007, PMID 41281055, PMID 9718381
2023 (1), P01NS044233 (1), P01NS119159 (1)